Not investment advice. Origin reports data from public SEC filings with cryptographic provenance. No buy/sell/hold recommendations. Past performance does not indicate future results.
This is the inaugural observation for IRWD on Origin, establishing a baseline as of August 19, 2026, with the stock trading at $4.36 against a $1B market cap on Nasdaq. The filing signal profile from the most recent 10-K is immediately notable: "strategic_event" appears with an unusually high match count of 136 (and a secondary cluster of 67), while "restructuring" registers 4 matches and "risk_factor" surfaces at both 41 and 7 counts across different filing sections. This pattern — heavy strategic event language alongside restructuring signals — is consistent with a company in active portfolio transition, likely reflecting Ironwood's ongoing efforts to define its identity post-separation from Cyclerion and its continued dependence on linaclotide (LINZESS) royalties and commercial operations. The 7 "ai_adoption" signals across three separate clusters (7, 4, and 3 matches) are worth flagging early; for a GI-focused pharmaceutical company, AI language in SEC filings at this density warrants scrutiny for whether it reflects genuine operational integration or boilerplate disclosure inflation. Zero transcripts captured on Origin and 249 all-time AI queries suggests moderate investor curiosity without deep institutional engagement on this platform. The absence of earnings call data is a meaningful analytical gap at this stage. Watch for: Q2 2026 earnings transcript capture to ground the filing signals in management commentary, any LINZESS royalty guidance revisions, and whether restructuring actions translate into updated operating expense trajectories.